A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2012
At a glance
- Drugs HSP 990 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 23 Aug 2012 Status changed from active, no longer recruiting to completed.
- 14 Mar 2012 Planned number of patients changed from 39 to 40 as reported by ClinicalTrials.gov.
- 14 Mar 2012 Planned End Date changed from 1 Jul 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.